PF-Atlas › Clinical Trials › NCT02649751

Evaluation of -Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Roscovitine · Phase 2

Registry ID

NCT02649751

Phase

Phase 2

Status

Terminated

Drug / intervention

Roscovitine

Sponsor

University Hospital, Brest

Start

2016-02-22

About this trial

Roscovitine is evaluated in NCT02649751, a Phase 2 idiopathic pulmonary fibrosis study sponsored by University Hospital, Brest. Current status: Terminated.

View NCT02649751 on ClinicalTrials.gov →

Explore related

All Roscovitine trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02649751 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.